文献速递肝病

CD14+CD15-HLA-DR-髓系来源抑制细胞损害慢加急性肝衰竭患者的抗菌反应

CD14+ CD15- HLA-DR- myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure.
PubMed 文献 · Gut · 2017-06-07

该研究对比慢加急性肝衰竭(ACLF)患者(n=41)与健康人(n=25)、肝硬化患者(n=22)及急性肝衰竭患者(n=30),发现ACLF患者循环CD14+CD15-CD11b+HLA-DR-髓系来源抑制细胞(M-MDSC)显著扩增且具有免疫抑制性,能抑制T细胞增殖、减少TLR刺激后TNF-α/IL-6产生并降低大肠埃希菌摄取;HLA-DR持续低表达与继发感染和28天死亡率相关;体外TLR-2/TLR-4刺激可扩增M-MDSC,而TLR-3激动可恢复HLA-DR表达及固有免疫功能。

要点

  • ACLF患者循环CD14+CD15-CD11b+HLA-DR- M-MDSC显著扩增至CD14+细胞的55%。
  • M-MDSC抑制T细胞增殖、减少TLR刺激后TNF-α/IL-6产生并降低大肠埃希菌摄取。
  • TLR-3激动可体外恢复HLA-DR表达和固有免疫功能,作者认为值得进一步评估。

核心结论

  • 免疫抑制性CD14+HLA-DR- M-MDSC在ACLF患者中扩增,抑制T细胞功能并削弱抗菌固有免疫反应,与继发感染、疾病严重度和预后相关。
  • TLR-3激动可逆转M-MDSC扩增并恢复固有免疫功能,作者认为值得进一步评估作为潜在免疫治疗药物。

研究设计与样本

  • 研究纳入ACLF患者(n=41),与健康受试者(n=25)、肝硬化患者(n=22)和急性肝衰竭患者(n=30)进行比较。
  • 按M-MDSC定义鉴定CD14+CD15-CD11b+HLA-DR-细胞,并进行详细免疫表型分析。
  • 用混合淋巴细胞反应评估对T细胞活化的抑制;用流式细胞术和活细胞成像技术评估固有免疫功能,包括对Toll样受体(TLR-2、TLR-4和TLR-9)刺激的细胞因子表达和吞噬试验。

主要发现

  • ACLF患者循环CD14+CD15-CD11b+HLA-DR- M-MDSC显著扩增,占CD14+细胞的55%。
  • M-MDSC表现出免疫抑制特性,显著降低T细胞增殖(p=0.01)。
  • M-MDSC对TLR刺激产生较少的肿瘤坏死因子-α/白细胞介素-6(所有p<0.01)。
  • M-MDSC降低对大肠埃希菌的细菌摄取(p<0.001)。
  • 疾病演变过程中HLA-DR持续低表达与继发感染和28天死亡率相关。

关键数值与推荐

  • 体外反复TLR-2和TLR-4刺激可扩增M-MDSC。
  • 体外TLR-3激动可恢复HLA-DR表达和固有免疫功能。

临床怎么用

  • 原文结论指出TLR-3激动可逆转M-MDSC扩增并恢复固有免疫功能,作者认为值得进一步评估作为潜在免疫治疗药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immune paresis in patients with acute-on-chronic liver failure (ACLF) accounts for infection susceptibility and increased mortality. Immunosuppressive mononuclear CD14+HLA-DR- myeloid-derived suppressor cells (M-MDSCs) have recently been identified to quell antimicrobial responses in immune-mediated diseases. We sought to delineate the function and derivation of M-MDSC in patients with ACLF, and explore potential targets to augment antimicrobial responses. DESIGN: Patients with ACLF (n=41) were compared with healthy subjects (n=25) and patients with cirrhosis (n=22) or acute liver failure (n=30). CD14+CD15-CD11b+HLA-DR- cells were identified as per definition of M-MDSC and detailed immunophenotypic analyses were performed. Suppression of T cell activation was assessed by mixed lymphocyte reaction. Assessment of innate immune function included cytokine expression in response to Toll-like receptor (TLR-2, TLR-4 and TLR-9) stimulation and phagocytosis assays using flow cytometry and live cell imaging-based techniques. RESULTS: Circulating CD14+CD15-CD11b+HLA-DR- M-MDSCs were markedly expanded in patients with ACLF (55% of CD14+ cells). M-MDSC displayed immunosuppressive properties, significantly decreasing T cell proliferation (p=0.01), producing less tumour necrosis factor-alpha/interleukin-6 in response to TLR stimulation (all p<0.01), and reduced bacterial uptake of Escherichia coli (p<0.001). Persistently low expression of HLA-DR during disease evolution was linked to secondary infection and 28-day mortality. Recurrent TLR-2 and TLR-4 stimulation expanded M-MDSC in vitro. By contrast, TLR-3 agonism reconstituted HLA-DR expression and innate immune function ex vivo. CONCLUSION: Immunosuppressive CD14+HLA-DR- M-MDSCs are expanded in patients with ACLF. They were depicted by suppressing T cell function, attenuated antimicrobial innate immune responses, linked to secondary infection, disease severity and prognosis. TLR-3 agonism reversed M-MDSC expansion and innate immune function and merits further evaluation as potential immunotherapeutic agent.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Bernsmeier C, Triantafyllou E, Brenig R, et al. CD14+ CD15- HLA-DR- myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. Gut. 2017. PMID: 28592438. doi:10.1136/gutjnl-2017-314184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。